The Wockhardt Injectable portfolio is a well-defined blending of anti-infectives, oncology adjuncts, pain relievers, anti-migraine and critical care products. Our product portfolio is poised to undergo rapid growth in a short period of time, as we plan to recommercialize 5 ANDA products presently in short supply as well as 11 additional ANDA products presently in various stages of development or pending regulatory approval. Our portfolio will be expanded to include products in infectious disease, renal disease, diuretics and blood modifiers.

Adenosine Injection

Adenosine Injection (2)

FDA Rating : AP

Compares To : Adenocard

View Products

Ceftriaxone for Injection

Ceftriaxone for Injection (4)

FDA Rating : AP

Compares To : Rocephin

View Products

Granisetron HCl Injection

Granisetron HCl Injection (2)

FDA Rating : AP

Compares To : Kytril

View Products

Ketorolac Tromethamine Injection

Ketorolac Tromethamine Injection (6)

FDA Rating : AP

Compares To : Toradol

View Products

Nicardipine HCl Injection

Nicardipine HCl Injection (1)

FDA Rating : AP

Compares To : Cardene IV

View Products

Ondansetron Injection

Ondansetron Injection (2)

FDA Rating : AP

Compares To : Zofran

View Products

Sumatriptan Injection

Sumatriptan Injection (1)

FDA Rating : AP

Compares To : Imitrex

View Products